The multiple sclerosis functional composite a clinically meaningful measure of disability

Neurology

Volumn 74, Issue 17 SUPPL. 3, 2010, Pages

  Polman, Chris H ^a   Rudick, Richard A ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; PLACEBO;

CLINICAL EVALUATION; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITION; CONSTRUCT VALIDITY; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RATING SCALE; RELAPSE; REMISSION; REVIEW; SCORING SYSTEM; SHORT FORM 36; SICKNESS IMPACT PROFILE; TEST RETEST RELIABILITY;

EID: 77951677636     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181dbb571     Document Type: Review

References (54)

1. Kurtzke JF. Rating neurologie impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
2. Kragt JJ, Nielsen JM, van der Linden FA, Uitdehaag BM, Polman CH. How similar are commonly combined crite-ria for EDSS progression in multiple sclerosis? Mult Scler 2006; 12: 782-786.
3. Interferon beta-lb is effective in relapsing-remitting multi-ple sclerosis. I. Clinical results of a multicenter, random-ized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993: 43: 655-661.
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.
5. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-la for disease progression in relapsing mul-tiple sclerosis. The Multiple Sclerosis Collaborative Re-search Group (MSCRG). Ann Neurol 1996; 39: 285-294.
6. Randomised double-blind placebo-controlled study of in-terferon beta-la in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Inter-feron beta-la Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504.
7. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
8. Rudick RA, Stuart WH, Gilabresi PA, et al; SENTINEL In-vestigators. Natalizumab plus interferon beta-la for re-lapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
9. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122(Pt 5): 871-882.
10. Rudick R, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996; 40: 469-479. (Pubitemid 26304809)
11. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Out-comes Assessment Task Force. Ann Neurol. 1997; 42: 379-382.
12. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1995; 1: 37-47.
13. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensi-tivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil 1988; 69: 850-854.
14. Kaufman M, Meyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis func-tional composite. Mult Scler 2000; 6: 286-290.
15. Gronwall DM. Paced auditory serial-addition task: a mea-sure of recovery from concussion. Percept Mot Skills 1977; 44: 367-373.
16. Cohen JA, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS functional composite out-come measure. Neurology 2000; 54: 802-806.
17. Cohen JA, Cutter GR, Fischer JS, et al, for the IMPACT Investigators. Use of the multiple sclerosis functional com-posite as an outcome measure in a phase 3 clinical trial. Arch Neurol. 2001; 58: 961-967.
18. Solari A, Radice D, Manneschi L, Motti L, Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components. J Neurol Sci 2005; 228: 71-74.
19. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. The National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999; 5: 244-250.
20. Fox RJ, Lee JC, Rudick RA. Optimal reference population for the multiple sclerosis functional composite. Mult Scler 2007; 13: 909-914.
21. Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001; 15: 247-258. (Pubitemid 32475720)
22. Kalkers NK, de Groot V, Lazeron RH, et al. MS func-tional composite: relation to disease phenotype and dis-ability strata. Neurology 2000: 54: 1233-1239.
23. Hoogervorst EL, Kalkers NF, Uitdehaag BM, Polman CH. A study validating changes in the multiple sclerosis functional composite. Arch Neurol 2002: 59: 113-116.
24. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol. 2000: 57: 1319-1324.
25. Kalkers NF, Bergers L, de Groot V, et al. Concurrent va-lidity of the MS Functional Composite using MRI as a biological, disease marker. Neurology 2001; 56: 215-219.
26. Kalkers NF, Bergers E, Castelijns JA, et al. Optimizing the association between, disability and biological markers in MS. Neurology 2001; 57: 1253-1258.
27. Vrenken H, Pouwels PJ, Ropele S, et al. Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Mult Scler 2007: 13: 708-716.
28. Khaleeli Z, Cercignani M, Audoin B, Ciccarelli O, Miller DH, Thompson AJ. Localized grey matter damage in early primary progressive multiple sclerosis contributes to dis-ability. Neuroimage 2007; 37: 253-261.
29. Khaleeli. Z, Sastre-Garriga J, Ciccarelli. O, Miller DH, Thompson AJ. Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2007; 78: 1076-1082.
30. Lowe MJ, Horenstein C, Hirsch JG, et al. Functional pathway-defined MRI diffusion measures reveal increased transverse diffusivity of water in multiple sclerosis. Neuroimage 2006; 32: 1127-1133.
31. Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in re-lapsing MS. Neurology 2001; 56: 1324-1330. (Pubitemid 32455292)
32. Fisher E, Rudick RA, Cutter G, et al. Relationship be-tween brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000: 6: 373-377.
33. Sastre-Garriga J, Ingle GT, Chard DT, Ramió-Torrentà L, Miller DH, Thompson AJ. Grey and white matter atrophy in early clinical stages of primary progressive multiple scle-rosis. Neuroimage 2004; 22: 353-359.
34. Chard DT, Griffin CM, McLean MA, et al. Brain metab-olite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple scle-rosis. Brain 2002;125(Pt 10): 2342-2352.
35. Jasperse B, Jakobs C, Eikelenboom MJ, et al. N-acetylaspartic acid in cerebrospinal fluid, of multiple sclero-sis patients determined by gas-chromatography-mass spectrometry. J Neurol 2007; 254: 631-637.
36. Moldovan IR, Rudick RA, Codeur AC, et al. Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progres-sion. J Neuroimmunol 2003; 141: 132-140.
37. van Veen T, Nielsen J, Berkhof J, et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol 2007; 190: 157-164.
38. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Mul-tiple Sclerosis Functional Composite (MSFC): Adminis-tration and. Scoring Manual. National Multiple Sclerosis Society: New York; 2001.
39. Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Ex-panded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler 2004; 10: 41-46.
40. Uitdehaag BM, Adèr HJ, Roosma TJA, de Groot V, Kalk-ers NF, Polman CH. Multiple sclerosis functional com-posite: impact of reference population and interpretation of changes. Mult Scler 2002; 8: 366-371.
41. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neurology 2002; 58: 1294-1296.
42. Uitdehaag BM, Adèr HJ, Kalkers NF, Polman CH. Quan-titative functional measures in MS: what is a reliable change? Neurology 2002; 59: 648-649.
43. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 2006; 60: 236-242.
44. Cohen JA, Cutter GR, Fischer JS, et al. IMPACT Investi-gators. Benefit of interferon beta-la on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-687.
45. Miller DM, Cohen JA, Kooijmans M, T'sao E, Cutter G, Baier M. Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study. Mult Scler 2006; 12: 180-186.
46. Kappas L, Freedman MS, Polman CH, et al. BENEFIT Study Group. Effect of early versus delayed interferon beta-lb treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389-397.
47. Montalban X. Overview of European pilot study of inter-feron beta-lb in primary progressive multiple sclerosis. Mult Scler 2004; 10(suppl 1): S62-S64.
48. Polman. CH, Rudick RA, Baker LJ, et al. Sustained dis-ability progression using scores from the Multiple Sclerosis Functional Composite. Presented. at the 59th Annual Meeting of the American Academy of Neurology; April 28-May 5, 2007; Boston.
49. Phillips JT, Kappos L, O'Connor PW, et al; for the AFFIRM Investigators. The effects of natalizumab mono-therapy on multiple sclerosis measures of disability pro-gression in patients with multiple sclerosis. Presented at the 58th Annual Meeting of the American Academy of Neurology; April 1-8, 2006; San Diego, CA.
50. Lublin FD, O'Connor PW, Havrdova E, et al; for the AFFIRM Investigators. The effects of natalizumab on dis-ability progression in the AFFIRM study: correlation be-tween changes in Multiple Sclerosis Functional Composite and Expanded Disability Status Scale scores (poster P580). Presented at the 21st Congress of the European Commit-tee for Treatment and Research in Multiple Sclerosis; Sep-tember 28-October 1, 2005; Thessaloniki, Greece.
51. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychologi-cal effects of interferon beta-1a in relapsing multiple scle-rosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48: 885-892.
52. Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999; 56: 319-324.
53. Fisher E, O'Connor PW, Havrdova E, et al; for the AF-FIRM Investigators. The effects of natalizumab on brain atrophy and cognitive function: results from the AFFIRM study (poster P383). Presented at the 22nd Congress of the European Committee for Treatment and Research in Mul-tiple Sclerosis; September 27-30, 2006; Madrid, Spain.
54. Kragt JJ, Thompson AJ, Montalban X, et al. Responsive-ness and predictive value of EDSS and MSFC in primary progressive MS. Neurology 2008; 70: 1084-1091.